The global market for Ion Channel Modulators is projected to decline to US$7.3 billion by 2022, weighed down by patent expirations, generic drug onslaught and lack of promising drugs in the pipeline. Despite data provided by the Human Genome Project use of ion channels as drug targets is limited by their extreme physiological, functional, and structural diversity, and restricted target validation for drug action. Types of ion channel modulators include Ligand-gated ion channels (LGICs), Voltage-gated ion channels (VGICs), aquaporins, and sodium leak channel, among others. The U.S. represents the largest market worldwide. While all other markets are witnessing erosion in growth and revenue, Asia-Pacific ranks as the only pocket of growth in the global market with a CAGR of 1.8% through the analysis period. The growth in the region is sustained by the low cost of ion channel research products as compared to other alternate technologies; tried and tested drug class and the resulting adoption of ion channel based drugs by the medical community; technological advancements in high-throughput screening methodologies; and the still high popularity of calcium channel blocking drugs and sodium channel blockers for cardiovascular diseases including arrhythmias.
DOMAIN EXPERT ENGAGEMENTS
Number of executives repeatedly engaged by snail & email outreach*
POOL + OUTREACH
Interactions with Platform & by Email *
Unique # Participated *
Responses Validated *